PHARMACOLOGY - PowerPoint PPT Presentation

1 / 35
About This Presentation
Title:

PHARMACOLOGY

Description:

Narcotic antitussives (codeine and hydrocodone) are used to treat the ... Dextromethorphan, codeine and hydrocodone may cause excitation, an extreme elevated temp. ... – PowerPoint PPT presentation

Number of Views:433
Avg rating:3.0/5.0
Slides: 36
Provided by: Don8162
Category:

less

Transcript and Presenter's Notes

Title: PHARMACOLOGY


1
PHARMACOLOGY
  • Respiratory drugs

2
OBJECTIVES
  • Identify the classes of drugs used to improve
    respiratory function.
  • Identify the uses and varying actions of these
    drugs.
  • Identify how these drugs are absorbed,
    distributed, metabolized, and excreted.
  • Identify drug interactions and adverse reactions
    to these drugs.

3
DRUGS AND THE RESPIRATORY SYSTEM
  • The respiratory system takes in oxygen and expels
    carbon dioxide.
  • Drugs used to improve respiratory function
    include methylxanthines, expectorants,
    antitussives, mucolytics, and decongestants.

4
METHYLXANTHINES
  • Used to treat breathing disorders.
  • Types of methylxanthines include anhydrous
    theophylline and its derivative salts,
    aminophylline, oxtriphylline, and theophylline
    sodium glycinate.

5
METHYLXANTHINES
  • Pharmacokinetics
  • Vary according to drug, dosage form, and
    administration route.
  • Absorbed rapidly and completely 60
    protein-bound in adults readily crosses the
    placental barrier secreted in breast milk
    metabolized primarily by the liver 10 excreted
    unchanged in the urine.

6
METHYLXANTHINES
  • Pharmacodynamics
  • Decrease airway reactivity and relieve
    bronchospasm by relaxing bronchial smooth muscle.
  • In nonreversible obstructive airway disease the
    drug increases the sensitivity of the brains
    respiratory center to CO2 and to stimulate the
    respiratory drive.

7
METHYLXANTHINES
  • In chronic bronchitis and emphysema, these drugs
    decrease fatigue of the diaphragm and improve
    ventricular function.

8
METHYLXANTHINES
  • Pharmacotherapeutics
  • Used to treat asthma, chronic bronchitis,
    emphysema, and neonatal apnea.

9
METHYLXANTHINES
  • Drug interactions
  • Smoking increases elimination, decreasing serum
    concentrations and effectiveness.
  • Taking adrenergic stimulants or drinking
    beverages that contain caffeine may result in
    additive adverse reactions.
  • Phenobarbital, phenytoin (Dilantin), rifampin,
    and carbamazepine (Tegretol) reduce levels.

10
METHYLXANTHINES
  • Receiving halothane, enflurane, isoflurane, and
    methoxyflurane increases the risk of cardiac
    toxicity.
  • May reduce the effects of lithium by increasing
    its rate of excretion.
  • Thyroid hormones may reduce levels.
  • Many drugs can increase levels resulting in
    toxicity.

11
OTHER DRUGS
  • Two other drugs used to relieve bronchospasm in
    acute asthma attacks include short-acting
    beta2-adrenergic agonists (Albuterol) and
    anticholinergics (Atropine).
  • Another drug used prevent asthma attacks (not
    treat acute asthma attacks) is cromolyn sodium
    (Intal, Nasalcrom).

12
EXPECTORANTS
  • These drugs thin mucous so its cleared more
    easily out of airways.
  • The most commonly used expectorant is guaifenesin
    (Robitussin).

13
EXPECTORANTS
  • Pharmacokinetics
  • Absorbed through the GI tract metabolized by the
    liver excreted primarily by the kidneys.

14
EXPECTORANTS
  • Pharmacodynamics
  • By increasing the production of respiratory tract
    fluids, expectorants reduce the thickness,
    adhesiveness, and surface tension of mucous,
    making it easier to clear from the airways.

15
EXPECTORANTS
  • Pharmacotherapeutics
  • Used for the relief of coughs from colds, minor
    bronchial irritation, bronchitis, influenza,
    sinusitis, bronchial asthma, emphysema, and other
    respiratory disorders.
  • May be taken with antitussives, analgesics,
    antihistamines, or decongestants.

16
EXPECTORANTS
  • Drug interactions
  • Administration with anticoagulants may increase
    the risk of bleeding.

17
ANTITUSSIVES
  • Suppress or inhibit dry, nonproductive coughing.
  • Include benzonatate (Tessalon), codeine,
    dextromethorphan hydrobromide, and hydrocodone
    bitartrate.

18
ANTITUSSIVES
  • Pharmacokinetics
  • Absorbed well through the GI tract metabolized
    by the liver excreted in the urine.

19
ANTITUSSIVES
  • Pharmacodynamics
  • Act in slightly different ways.
  • Benzonatate acts by anesthetizing stretch
    receptors throughout the bronchi, alveoli, and
    pleura.
  • The others suppress the cough reflex by direct
    action on the cough center in the medulla of the
    brain.

20
ANTITUSSIVES
  • Pharmacotherapeutics
  • Used to treat a serious, nonproductive cough that
    interferes with a patients ability to rest and
    perform ADLs.
  • Benzonatate relieves cough caused by pneumonia,
    bronchitis, the common cold, and COPD.
  • Also used during diagnostic procedures.

21
ANTITUSSIVES
  • Dextromethorphan is the most widely used because
    of its effectiveness and few adverse reactions.
  • Narcotic antitussives (codeine and hydrocodone)
    are used to treat the intractable cough
    associated with lung CA.

22
ANTITUSSIVES
  • Drug interactions
  • Dextromethorphan, codeine and hydrocodone may
    cause excitation, an extreme elevated temp.,
    hypertension, hypotension, and coma when taken
    with MAO inhibitors.
  • Codeine may cause CNS depression when taken with
    other CNS depressants.

23
MUCOLYTICS
  • Act directly on mucous, breaking down sticky,
    thick secretions so theyre more easily
    eliminated.
  • Acetylcysteine (Mucomyst) is the only thiol
    compound mucolytic used clinically in the U.S.

24
MUCOLYTICS
  • Pharmacokinetics
  • When inhaled is absorbed from the pulmonary
    epithelium when taken orally is absorbed from
    the GI tract.
  • Metabolized in the liver excretion is unknown.

25
MUCOLYTICS
  • Pharmacodynamics
  • Decreases the thickness of respiratory tract
    secretions by altering the molecular composition
    of mucous.

26
MUCOLYTICS
  • Pharmacotherapeutics
  • Used with other therapies to treat patients with
    abnormal or thick mucous secretions such as those
    with bronchitis, emphysema, cystic fibrosis, or
    atelectasis.
  • Used as a bronchial study prep.
  • Is the antidote for acetaminophen overdose.

27
MUCOLYTICS
  • Drug interactions
  • Activated charcoal decreases effectiveness,
    therefore, when using drug to treat acetaminophen
    overdose, remove activated charcoal from the
    stomach.

28
DECONGESTANTS
  • Classified as systemic or topical.
  • Systemic decongestants stimulate the sympathetic
    nervous system to reduce swelling of the
    respiratory tracts vascular network.
  • Drugs include ephedrine, phenylpropanolamine,
    and pseudoephedrine (Sudafed).

29
DECONGESTANTS
  • When applied directly to swollen mucous membranes
    of the nose, topical decongestants provide
    immediate relief from nasal congestion.
  • These drugs include ephedrine, epinephrine,
    phenylephrine, Prototype naphazoline (Afrin),
    oxymetazoline, tetrahydrozoline, and
    xylometazoline.

30
DECONGESTANTS
  • Pharmacokinetics
  • Properties vary among drugs.
  • Systemic drugs when taken orally are readily
    absorbed from the GI tract widely distributed
    throughout the body, including CSF, placenta, and
    breast milk metabolized slowly and incompletely
    in the liver excreted largely unchanged in the
    urine.

31
DECONGESTANTS
  • Topical decongestants act directly on the alpha
    receptors of the vascular smooth muscle in the
    nose, causing the arterioles to constrict,
    resulting in very little of the drug being
    absorbed.

32
DECONGESTANTS
  • Pharmacodynamics
  • Systemic decongestants cause vasoconstriction by
    stimulating alpha-adrenergic receptors in the
    blood vessels in the nasal mucosa.
  • Topical decongestants work the same as systemic
    ones, however, the reduced blood flow to the
    nasal mucous membranes reduces swelling.

33
DECONGESTANTS
  • Pharmacotherapeutics
  • Used to relieve the symptoms of swollen nasal
    membranes resulting from hay fever, allergic
    rhinitis, vasomotor rhinitis, acute coryza,
    sinusitis, and the common cold.
  • Systemic decongestants are frequently given with
    antihistamines, antipyretics-analgesics,
    antitussives, and expectorants.

34
DECONGESTANTS
  • Topical decongestants provide two major
    advantages over systemics minimal adverse
    reactions and rapid symptom relief.

35
DECONGESTANTS
  • Drug interactions
  • Because of vasoconstriction, topical drug
    interactions seldom occur.
  • Increased CNS stimulation may occur when taken
    with other sympathomimetic drugs.
  • Taken with MOA inhibitors may cause severe
    hypertension or a hypertensive crisis.
  • Alkalinizing drugs may increase the effects of
    pseudoephedrine.
Write a Comment
User Comments (0)
About PowerShow.com